HOME >> BIOLOGY >> NEWS
Newly discovered protein could hold key to preventing heart disease

A newly discovered gene known as MCPIP could provide scientists with the key to developing treatments for preventing inflammation that can cause heart disease, University of Central Florida researchers have discovered.

A research team led by Pappachan Kolattukudy, dean of the UCF Burnett College of Biomedical Sciences, found that the levels of MCPIP increased in mice as their blood vessels became inflamed and heart disease began to develop. The formation of MCPIP leads to the death of healthy cells, so treatments that block that formation could prove effective for heart disease.

The researchers are trying to discover the molecular changes that occur as heart disease develops. Better understanding those molecular changes would help with the development of drugs that can either prevent or treat the disease.

The team's findings are published in the May 12 issue of Circulation Research, the journal of the American Heart Association. The research is funded through a $1.4 million grant from the National Institutes of Health.

The laboratory mice developed heart disease in a way similar to how it forms in humans, which suggests that the findings could hold promise for treating human heart disease. However, more research is needed to evaluate whether the same results found in mice could be expected in humans.

The UCF research team already has found that MCPIP is elevated in human hearts suffering ischemic heart failure.

MCPIP is formed when an often-studied protein called MCP-1 binds to receptors. The MCP-1 protein helps to attract white blood cells known as monocytes to infected and injured areas of the body. The monocytes then attack bacteria and help the body fight diseases.

But that process also produces several known and unknown proteins. The researchers focused on MCPIP, one of the previously unknown proteins, because they discovered links between it and the deaths of healthy cells adjacent to the infected one
'"/>

Contact: Chad Binette
cbinette@mail.ucf.edu
407-823-6312
University of Central Florida
17-May-2006


Page: 1 2

Related biology news :

1. Newly created cancer stem cells could aid breast cancer research
2. Newly identified mechanism for silencing genes points to possible anti-cancer strategies
3. Newly discovered platform for processing dietary fat
4. Newly discovered West Coast arrhythmias cause
5. Newly discovered fish named after New York aquarium biologist
6. Newly discovered immune defense may be impaired in CF airways
7. Newly identified strains of Chlamydia trachomatis could produce new diseases
8. Newly discovered proteins associated with cystic fibrosis
9. Newly discovered gene may hold clues to evolution of human brain capacity
10. Newly identified protein complex sheds light on axon growth mechanism
11. Newly discovered protein kills anthrax bacteria by exploding their cell walls

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Newly discovered protein could hold key preventing heart disease

(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report ... markets for Iris Biometrics in US$ Thousands. The report provides ... , Japan , Europe ... , and Latin America . ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
(Date:4/16/2015)... Morton Grove, IL (PRWEB) April 16, 2015 ... the American Association for Cancer Research (AACR) ... at the Pennsylvania Convention Center, starting Saturday, April 18, ... The AACR holds claim to title of the oldest ... several journals, provides fellowships and grants, and partners with ...
(Date:4/16/2015)... The Council for Agricultural Science and ... CAST Communication Award goes to Dr. Channapatna Prakash, ... Alabama. Award nominees must demonstrate an ability to ... use of television, radio, or other social media. ... specialist in the field of plant genetics and ...
(Date:4/16/2015)... Md. , April 16, 2015  RegeneRx ... today announced its U.S. joint venture with G-treeBNT ... a phase 3 clinical trial for the orphan ... confirmatory trial for dry eye syndrome (DES) in ... preservative-free eye drops, RGN-259/GBT201, this year.  Each of ...
(Date:4/16/2015)... A new infographic compiles useful information ... institutions to learn how Appleā€™s new framework can change ... is ideal since Apple made Research Kit ... open-source framework for developing medical research apps that Apple ... researchers to collect secure clinical data and communicate via ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2The 2015 Borlaug CAST Communication Award Goes to Channapatna Prakash 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Infographic Illustrates Potential for Research Kit to Impact Clinical Research 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 3
Cached News: